Pharmacoresistance - Epidemiology, mechanisms, and impact on epilepsy treatment
Mubeen Janmohamed, Martin J Brodie, Patrick Kwan
Neuropharmacology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2020
Understanding the natural history of and factors associated with pharmacoresistant epilepsy provides the foundation for formulating mechanistic hypotheses that can be evaluated to drive the development of novel treatments. This article reviews the modern definition of drug-resistant epilepsy, its prevalence and incidence, risk factors, hypothesized mechanisms, and the implication of recognizing pharmacoresistance in therapeutic strategies. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
Awarded by Medical Research Future Fund Practitioner Fellowship
Mubeen Janmohamed receives support through an "Australian Government Research Training Program (RTP) Scholarship" for PhD at Monash University, Central Clinical School, Melbourne Australia. Patrick Kwan is supported by the Medical Research Future Fund Practitioner Fellowship (MRF1136427).